Key Takeaway
How to Verify a Telehealth Weight Loss Company. Evidence-based answers from FormBlends, a physician-supervised telehealth weight loss clinic.
Here is what the current medical evidence says about how to verify a telehealth weight loss company. At FormBlends, our physicians stay on top of the latest research to give patients clear, actionable information. Below we break down what you need to know, based on clinical data and our clinical experience.
What Does the Research Say About How to Verify a Telehealth Weight Loss Company?
The medical literature on how to verify a telehealth weight loss company provides several key findings:
- GLP-1 receptor agonists work by mimicking natural gut hormones that regulate appetite and blood sugar
- Clinical trials have shown consistent weight loss results across diverse patient populations
- Side effects are primarily gastrointestinal and tend to improve during the first weeks of treatment
- Physician supervision is important for monitoring progress and adjusting dosing
How Does This Apply to Your Treatment?
Knowing how to verify a telehealth weight loss company matters because it directly affects treatment decisions. At FormBlends, our physicians consider this information when building your personalized protocol. Every patient is different, and what works for one person may need adjustment for another.
View data table
| Category | Search Volume Share (%) | Detail |
|---|---|---|
| Side Effects | 35 | Nausea, GI issues |
| Cost/Insurance | 28 | Pricing questions |
| Effectiveness | 22 | How much weight loss |
| Eligibility | 15 | BMI requirements |
We recommend discussing how to verify a telehealth weight loss company with your FormBlends physician during your consultation. They can explain how it applies to your specific health history and weight loss goals.
Clinical Evidence for GLP-1 Weight Loss Medications
GLP-1 receptor agonists have demonstrated significant weight loss efficacy in large-scale clinical trials. The STEP clinical trial program for semaglutide showed participants achieved average weight loss of 14.9% over 68 weeks when combined with lifestyle interventions. Tirzepatide performed even better in the SURMOUNT-1 trial[1], with participants losing up to 22.5% of body weight[1] at the highest 15mg dose. These medications work by slowing gastric emptying, reducing appetite, and improving insulin sensitivity.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Liraglutide (Saxenda), the first FDA-approved GLP-1 for weight loss in 2014, demonstrated 8% average weight loss[3] in clinical trials. The medication requires daily injections, while newer options like semaglutide (weekly) and tirzepatide (weekly) offer improved convenience. Clinical data shows these medications are most effective when prescribed by licensed physicians who can monitor for side effects like nausea, vomiting, and potential pancreatitis, which occur in 5-20% of patients during dose escalation phases.
Clinical Evidence
The STEP-1 trial[2] showed 83.5% of patients on semaglutide achieved 5% weight loss compared to 31.1% on placebo. SURMOUNT-1 demonstrated that 91% of tirzepatide patients achieved clinically significant[1] weight loss versus 35% with placebo.
What Should You Do Next?
If you have questions about how to verify a telehealth weight loss company, FormBlends can help. Our licensed physicians provide personalized guidance based on your medical history and goals. Start with a free online evaluation to connect with a provider who can answer your specific questions.
- Semaglutide for weight loss
- Tirzepatide for weight loss
- Compounded GLP-1 medications
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. [PubMed | ClinicalTrials.gov | DOI]
Get Personalized Answers
General information is a starting point, but your treatment should be tailored to you. FormBlends connects you with licensed physicians who can evaluate your situation and provide specific recommendations. Complete your free evaluation today.